MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)

Merck Sharp & Dohme (MSD)

Status and phase

Completed

Phase 2

Conditions

Diabetes Mellitus, Type 2

Metabolic Syndrome

Treatments

Drug: MK0916

Study type

Interventional

Funder types

Industry

Identifiers

NCT00543595

2007_643

0916-005

Details and patient eligibility

About

This study will test the safety and effectiveness of MK0916 in patients with Type 2 Diabetes Mellitus and Metabolic Syndrome.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Enrollment

154 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Have Type 2 Diabetes
18 to 65 years of age

Exclusion criteria

History of Type 1 Diabetes Mellitus
Have been treated with insulin in the past 8 weeks
On a weight loss program and have ongoing weight loss
Taking weight loss medication
Have had surgery requiring general anesthesia in the past 30 days or have a planned surgery
Have taken another investigational drug in the last 8 weeks
Have active liver disease
Have a history of major surgery involving gastric or intestinal bypass